MGTX - メイラGTxホ―ルディングス (MeiraGTx Holdings plc) メイラGTxホ―ルディングス

 MGTXのチャート


 MGTXの企業情報

symbol MGTx
会社名 MeiraGTx Holdings PLC (メイラGTxホ―ルディングス)
分野(sector) Health Care   ヘルスケア
産業(industry) Biotechnology: Biological Products (No Diagnostic Substances)  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 メイラ・ジー・ティー・エックス・ホールディングス(MeiraGTx Holdings plc)は臨床段階の遺伝子治療事業に従事する会社である。同社は、一連の遺伝性疾患及び後天性疾患の遺伝子治療技術を開発する。同社は主に、遺伝性失明症、口腔乾燥症、頭頸部癌の放射線治療、及び甲状腺機能低下症(ALS)などの神経変性疾患を含む眼疾患の治療法開発に従事する。また、小分子の使用により遺伝子治療製品の候補を有効または無効にするための変革技術を開発する。同社は、遺伝性網膜疾患、重度の形態の口腔乾燥症及び神経変性疾患を含む、満たされていない医療ニーズの3つの分野に集中する。同社の製品には、AAV-CNGB3 AAV-CNGA3 AAV-RPGR AAV-RPE65 A006 AAV-AQP1及びAAV-UPF1を含む。   メイラGTxホ―ルディングスは米国のバイオ医薬品企業。目、唾液腺および中枢神経系の疾患に対する遺伝子治療法の開発に焦点を当て事業を行う。進行中の臨床プログラムのほか、前臨床および臨床段階の研究プログラムの幅広いパイプラインを保有し、遺伝子治療薬の製造を手掛ける。また、形質転換型の遺伝子制御技術を提供する。本社所在地はニューヨーク。   MeiraGTx is a vertically integrated, clinical stage gene therapy company with six programs in clinical development and a broad pipeline of preclinical and research programs. MeiraGTx has core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, MeiraGTx has taken a portfolio approach by licensing, acquiring and developing technologies that give depth across both product candidates and indications. MeiraGTx's initial focus is on three distinct areas of unmet medical need: ocular, including inherited retinal diseases and large degenerative diseases, neurodegenerative diseases and severe forms of xerostomia. Though initially focusing on the eye, central nervous system and salivary gland, MeiraGTx intends to expand its focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases.
本社所在地 430 East 29th Street 10th Floor New York NY 10016 USA
代表者氏名
代表者役職名
電話番号
設立年月日 43221
市場名 NASDAQ National Market System
ipoyear 2018年
従業員数 59人
url www.meiragtx.com
nasdaq_url https://www.nasdaq.com/symbol/mgtx
adr_tso
EBITDA EBITDA(百万ドル) -59.48334
終値(lastsale) 13.255
時価総額(marketcap) 360325669.66
時価総額 時価総額(百万ドル) 363.14670
売上高 売上高(百万ドル) 0.00000
企業価値(EV) 企業価値(EV)(百万ドル) 261.13565
当期純利益 当期純利益(百万ドル) -65.98993
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 MeiraGTx Holdings PLC revenues was not reported. Net loss applicable to common stockholders increased from $14.1M to $48.2M. Higher net loss reflects General and administrative increase from $2.1M to $17.7M (expense) Stock-based Compensation in SGA increase from $131K to $10.8M (expense) Research and development increase from $4.8M to $12.8M (expense).

 MGTXのテクニカル分析


 MGTXのニュース

   MeiraGTx Announces $60 Million Private Placement of Ordinary Shares  2023/05/03 12:30:00 GlobeNewswire
LONDON and NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that it has agreed to sell approximately 10.7 million ordinary shares at a price of $5.75 per share. MeiraGTx anticipates aggregate gross proceeds from the private placement will be approximately $60 million. The Company intends to use the proceeds from this private placement to continue to advance its pipeline of innovative gene therapy assets through clinical development, as well as for general corporate purposes.
   MeiraGTx Holdings plc PT Lowered to $22 at RBC Capital  2023/03/15 12:43:01 Investing.com
https://www.investing.com/news/pro/meiragtx-holdings-plc-pt-lowered-to-22-at-rbc-capital-432SI-3031219
   MeiraGTx Holdings plc (NASDAQ: MGTX) Shares Fall :-682.03% From The Trough – But Can It Keep Going?  2022/12/24 15:00:00 Marketing Sentinel
MeiraGTx Holdings plc (NASDAQ:MGTX)’s traded shares stood at 0.41 million during the last session, with the company’s beta value hitting 1.42. At the close of trading, the stock’s price was $6.01, to imply a decrease of -0.66% or -$0.04 in intraday trading. The MGTX share’s 52-week high remains $24.89, putting it -314.14% down since that … MeiraGTx Holdings plc (NASDAQ: MGTX) Shares Fall :-682.03% From The Trough – But Can It Keep Going? Read More »
   How should investors view MeiraGTx Holdings plc (MGTX)?  2022/12/14 16:16:00 US Post News
As of Tuesday, MeiraGTx Holdings plc’s (NASDAQ:MGTX) stock closed at $6.11, down from $6.12 the previous day. While MeiraGTx Holdings plc has underperformed by -0.25%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, MGTX fell by -70.61%, with highs and lows ranging from $24.89 to $5.70, […]
   MeiraGTx''s Investigational Candidate Shows Improvement In Radiation Induced Dry Mouth Symptoms  2022/12/13 18:56:11 Benzinga
MeiraGTx Holdings plc (NASDAQ: MGTX ) announced positive clinical data from the ongoing Phase 1 AQUAx study of AAV2-hAQP1 for grade 2/3 radiation-induced xerostomia (RIX), dry mouth symptoms. Clinically meaningful improvements in xerostomia symptoms were reported consistently across two validated PROs assessing xerostomia symptom severity. Meaningful … Full story available on Benzinga.com
   MeiraGTx''s Industry-Leading Gene Therapy Manufacturing Facility in Shannon, Ireland Formally Introduced by Head of Irish Government  2022/09/16 06:00:00 Benzinga
-- Manufacturing facilities built to accelerate development and delivery of advanced medicines to patients using state-of-the-art technology at scale, with quality appropriate for commercialization -- Site reflects MeiraGTx''s unique, end-to-end approach to gene therapy manufacturing to expedite clinical development LONDON and NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX ), a vertically integrated, clinical stage gene therapy company, will today formally unveil its GMP manufacturing facility in Shannon, Ireland, with the Head of Irish Government, Micheál Martin, in attendance. The facility, online since earlier this year and stretching over 150,000 square feet, is the first commercial-scale gene therapy manufacturing site in Ireland. The facility is unique in its scale and integrated capabilities. The site contains three facilities, one built to be flexible and scalable for viral vector production for clinical and commercial supply, in addition, a facility to manufacture plasmid DNA – the critical starting material for producing gene therapy products – and thirdly, a Quality Control (QC) hub performing advanced biochemical quality control testing for MeiraGTx clinical and commercial programs.
   MeiraGTx Holdings (MGTX) Investor Presentation - Slideshow (NASDAQ:MGTX)  2022/08/11 18:01:50 Seeking Alpha
The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event.
   MeiraGTx Posts Encouraging Gene Therapy Data From Eye Disorder Trial  2022/06/28 18:28:42 Benzinga
MeiraGTx Holdings plc (NASDAQ: MGTX ) announced topline data from the Phase 1/2 study MGT009 of botaretigene sparoparvovec, gene therapy for X-linked retinitis pigmentosa (XLRP). Treatment with botaretigene sparoparvovec was found to be generally safe and well-tolerated. Significant improvements were demonstrated across retinal, visual functions, and functional vision in participants treated with botaretigene sparoparvovec compared to the randomized untreated control … Full story available on Benzinga.com
   MeiraGTx (MGTX) Investor Presentation - Slideshow  2022/05/20 20:07:34 Seeking Alpha
The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event.
   MeiraGTx (NASDAQ:MGTX) Sees Large Volume Increase  2021/12/21 16:46:42 Dakota Financial News
Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) saw an uptick in trading volume on Tuesday . 5,580 shares traded hands during mid-day trading, a decline of 97% from the previous sessions volume of 187,077 shares.The stock last traded at $22.23 and had previously closed at $21.23. Several research firms have issued reports on MGTX. Bank of []
   MeiraGTx (MGTX) Investor Presentation - Slideshow  2022/05/20 20:07:34 Seeking Alpha
The following slide deck was published by MeiraGTx Holdings plc in conjunction with this event.
   MeiraGTx (NASDAQ:MGTX) Sees Large Volume Increase  2021/12/21 16:46:42 Dakota Financial News
Shares of MeiraGTx Holdings plc (NASDAQ:MGTX) saw an uptick in trading volume on Tuesday . 5,580 shares traded hands during mid-day trading, a decline of 97% from the previous sessions volume of 187,077 shares.The stock last traded at $22.23 and had previously closed at $21.23. Several research firms have issued reports on MGTX. Bank of []
   MeiraGTx to Host a Virtual Research and Development Day on Gene Regulation  2021/12/14 21:30:00 Benzinga
LONDON and NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX ), a vertically integrated, clinical stage gene therapy company, will host a virtual R&D Day via webcast and conference call on Wednesday, December 15, 2021, from 10:00 a.m. to 12:00 p.m. ET highlighting the Company''s gene regulation platforms. MeiraGTx''s R&D Day webcast will feature a presentation by Alexandria Forbes, Ph.D., President and Chief Executive Officer. The event will provide a detailed overview of the Company''s gene regulation platforms including promoter engineering and MeiraGTx''s proprietary platform driven by novel synthetic riboswitches controlled by oral small molecules. The presentation will be followed by an audience question and answer session. MeiraGTx''s virtual R&D Day details are as follows: Wednesday, December 15, 2021, from Full story available on Benzinga.com
   MeiraGTx to Provide a Xerostomia Clinical Program Update and Host a Virtual Research and Development Day on Gene Regulation  2021/11/29 21:30:00 Intrado Digital Media
LONDON and NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced it will host a conference call and webcast to provide an update on the Company’s AAV-hAQP1 Phase 1 AQUAx clinical trial for the treatment of radiation-induced xerostomia (RIX) on Tuesday, December 7, 2021, at 8:00 a.m. ET.
   Vanguard Group Inc. Reduces Stock Holdings in MeiraGTx Holdings plc (NASDAQ:MGTX)  2021/11/25 09:16:41 Dakota Financial News
Vanguard Group Inc. lessened its stake in shares of MeiraGTx Holdings plc (NASDAQ:MGTX) by 5.8% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 182,470 shares of the companys stock after selling 11,195 shares during the quarter. Vanguard Group Inc.s holdings in MeiraGTx were worth $2,829,000 at the end of the most recent quarter. []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 メイラGTxホ―ルディングス MGTX MeiraGTx Holdings plc)

 twitter  (公式ツイッターやCEOツイッターなど)